SLC6A1 and epilepsy: Regarding the abnormal EEG phenotypes in heterozygous Slc6a1+/– mice, both neonatal P1 ICV and P5 i.t. treated mice displayed therapeutic benefit (substantially normalized EEG epilepsy patterns) from AAV9/MeP-hSLC6A1 or AAV9/JeT-hSLC6A1 treatment (Figure 2).